Apply for the new Internal Grant Agency FM Accelerate call!
Get up to CZK 1,000,000 to develop your research with potential for practical application!
Life Science Transfer Academy is a joint educational program of JIC Innovation Agency, MUNI MED, MUNI PHARM, MUNI SCI, CEITEC MUNI and TTO MUNI focusing on key aspects of technology transfer in the life sciences.
The programme is intended for anyone who wants to better understand how their research can be translated into practice — through collaboration, licensing, or the creation of future spin-off companies.
Participants will learn how to transform research into market-ready innovations through intellectual property protection, industry collaboration, commercialization, and the creation of spin-off companies.
Are you ready to move your research toward practical results with commercial impact?
You can register until July 30, 2026!
Join 8 training sessions taking place from September 30 to December 2, 2026, every Wednesday from 1:00 to 5:00 PM at CEITEC MU.
The course is open not only to PhD candidates, pregradual students, but also to those in the postdoctoral stage of their research careers.
To enroll, please complete the registration form on the JIC website. All applications will be reviewed and the number of places are limited!
The entire programme is in English.
Upon successful completion, you will receive:
For more information about the course and to access the registration form, click below:
Life Science Transfer Academy - registration
Get up to CZK 1,000,000 to develop your research with potential for practical application!
What happens when a patient does not have access to sufficiently effective or appropriate treatment? Under precisely defined conditions, a hospital exemption may allow access to an unapproved advanced therapy medicinal product. This can offer patients with rare or serious diseases a treatment option that would otherwise be unavailable to them. The first hospital exemption in the Czech Republic was granted to the CREATIC Center of Excellence at the Faculty of Medicine for dendritic cell-based anticancer immunotherapy.